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Abstract
Macrophages are characterized by a high plasticity in response to
changes in tissue microenvironment, which allows them to acquire
different phenotypes and to exert essential functions in complex
processes, such as tissue regeneration. Here, we report that the
membrane protein Cripto plays a key role in shaping macrophage
plasticity in skeletal muscle during regeneration and disease.
Conditional deletion of Cripto in the myeloid lineage (CriptoMy-LOF)
perturbs MP plasticity in acutely injured muscle and in mouse
models of Duchenne muscular dystrophy (mdx). Specifically,
CriptoMy-LOF macrophages infiltrate the muscle, but fail to properly
expand as anti-inflammatory CD206+ macrophages, which is due,
at least in part, to aberrant activation of TGFb/Smad signaling. This
reduction in macrophage plasticity disturbs vascular remodeling
by increasing Endothelial-to-Mesenchymal Transition (EndMT),
reduces muscle regenerative potential, and leads to an exacerba-
tion of the dystrophic phenotype. Thus, in muscle-infiltrating
macrophages, Cripto is required to promote the expansion of the
CD206+ anti-inflammatory macrophage type and to restrict the
EndMT process, providing a direct functional link between this
macrophage population and endothelial cells.
Keywords Cripto; Duchenne muscular dystrophy; Endothelial-to-Mesenchymal
Transition; macrophage plasticity; skeletal muscle regeneration
Subject Categories Immunology; Molecular Biology of Disease; Signal
Transduction
DOI 10.15252/embr.201949075 | Received 14 August 2019 | Revised 6 February
2020 | Accepted 10 February 2020
EMBO Reports (2020) e49075
Introduction
Skeletal muscle regeneration relies on highly coordinated sequen-
tial events, which involve a complex network of interaction
between tissue-resident and recruited cells, including muscle stem
cells, inflammatory cells, endothelial-derived progenitors, and
fibro/adipogenic progenitors (FAPs) [1]. Progressive impairment of
the interplay between the inflammatory cells, mainly the infiltrated
macrophages, and the different muscle cellular components is
emerging as a key event in switching regeneration from compen-
satory to pathogenic regeneration [2]. Macrophages exhibit
substantial plasticity and can quickly change their phenotype in
response to different stimuli in the microenvironment. This unique
feature makes them serve different functions during the process of
skeletal muscle regeneration, including resolution of the pro-
inflammatory phase and transition to the regeneration phase. Soon
after an acute injury, invading macrophages adopt a pro-inflamma-
tory phenotype, phagocyte necrotic tissue, and secrete growth
factors, promoting an environment that favors satellite cell activa-
tion and proliferation [3–5]. Subsequently, a second wave of
macrophages with anti-inflammatory phenotype suppresses the
process of inflammation and supports restorative function. These
anti-inflammatory macrophages arise from resident macrophages
and/or circulating pro-inflammatory macrophages that switch into
an anti-inflammatory phenotype [6]. Besides supporting myoblast
differentiation, anti-inflammatory macrophages produce angiogenic
factors promoting vascular remodeling, which is necessary for a
proper regenerative process [7]. Furthermore, macrophages
promote the differentiation of endothelial-derived progenitors by
inhibiting a process known as the Endothelial-to-Mesenchymal
Transition (EndMT) process, in which endothelial cells acquire
myofibroblastic traits while losing endothelial-specific gene expres-
sion [8–10]. While in acute muscle injury, macrophages adopt
well-coordinated sequential waves of pro- and anti-inflammatory
phenotypes, this balance is skewed in chronic muscle diseases like
muscular dystrophies, where muscles fail to regenerate and the
tissue is progressively substituted by adipocytes and collagen fibers
[11,12]. Emerging evidence indicates that different macrophage
populations with mixed phenotypes coexist in dystrophic muscles,
but their precise function is only recently starting to be
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characterized [13]. Research efforts are currently focused on under-
standing how macrophage plasticity is controlled and how macro-
phages crosstalk with other muscle populations in injured and
dystrophic muscles. Recent findings from our laboratory and others
place the extracellular membrane protein Cripto within this
complex regulatory network. Cripto is a glycosylphosphatidylinosi-
tol (GPI)-anchored protein and acts as coreceptor for different
members of the TGF-b superfamily [14]. Of note, depending on the
context it also exists as a soluble protein either secreted or shed
from the membrane [15,16]. Cripto is a developmental gene known
to regulate early embryonic development [17,18] and it is usually
not expressed in normal adult tissues including resting skeletal
muscles. However, Cripto becomes rapidly and transiently re-
expressed upon acute injury both in activated/proliferating satellite
cells and in a subpopulation of infiltrating macrophages [19].
Emerging evidence indicates that Cripto is a key regulator of the
myogenic program during skeletal muscle regeneration [16,19,20].
However, no studies have been reported so far on the inflamma-
tory cell/macrophage-specific role of Cripto in skeletal muscle
regeneration. Here, we show in vivo evidence that Cripto is prefer-
entially expressed by anti-inflammatory macrophages and is a key
regulator of macrophage plasticity in injured and in dystrophic
skeletal muscles. Moreover, we suggest that Cripto mediates the
crosstalk between macrophages and endothelial cells promoting
vascular remodeling, at least in part, by restricting TGF-b-induced
EndMT and preventing excessive fibrosis in dystrophic muscles.
Results
Expression profile of cell-surface Cripto in subpopulations of
macrophages during acute muscle injury
The timely attraction of macrophages (MPs), the ordered transition
between the pro- and anti-inflammatory phenotypes, and the precise
termination of their activity are prerequisites for a successful regen-
eration process [4]. Cripto is expressed in the MPs that infiltrate the
injured muscle [19]; yet, the dynamics of Cripto expression in the
pro- and anti-inflammatory MPs was not investigated so far. To
address this issue directly, hind limb muscles of wild-type mice
were injected with cardiotoxin (CTX) and the expression of Cripto
in the different inflammatory cell populations was analyzed at days
2, 3, and 5 after injury (Fig 1A). To this end, injured muscles were
dissociated by enzymatic digestion and the bulk cells were stained
for Cripto and the MP markers CD11b, F4/80, and Ly6C. We first
assessed the expression of Cripto in the CD11b+ immune cells at
the different time points after injury; the number of CD11b+ that
expressed Cripto progressively increased from days 2 to 5 up to
40% (6.5  0.7% at day 2 vs. 40.7  1.3% at day 5; n = 5;
P = 1.14E-08; Figs 1B and EV1A), consistent with previous data of
Cripto expression in the infiltrating MPs [19]. We then examined
the distribution of pro-inflammatory (F4/80+/Ly6CHigh) and anti-
inflammatory (F4/80+/Ly6CLow) MPs in the CD11b+ cells through-
out the time course (Fig 1C). As expected, while the F4/80+/
Ly6CLow MPs (blue) and F4/80+/Ly6CHigh MPs (red) were almost
equally distributed in the CD11b+ cells at day 2, from day 3 onward
a dramatic increase in F4/80+/Ly6CLow MPs was observed, at the
expense of the F4/80+/Ly6CHigh MPs (Fig 1C and D). Finally, to
directly examine the nature of the Cripto+ immune cells, we evalu-
ated the distribution of F4/80+/Ly6CHigh and F4/80+/Ly6CLow MPs
in the CD11b+/Cripto+ population. Of note, the F4/80+/Ly6CLow
MPs were the vast majority at all the time points analyzed (Fig 1C
and D).
The gradual increase in Cripto expression levels in the CD11b+/
F4/80+/Ly6CLow MP population was detected by qRT–PCR
(Fig EV1B). Collectively, these results indicate that Cripto progres-
sively increased in the immune cells that infiltrate the injured
muscle and predominantly accumulated at the surface of anti-
inflammatory MPs, concomitantly with their accumulation in the
regenerating tissue.
Cripto controls MP plasticity
To investigate the physiological role of Cripto in the infiltrating MPs
without interfering with its activity in the myogenic compartment
[19], we generated myeloid-specific Cripto knockout (KO) mice. Tg:
Criptofl/fl conditional mice [21] were crossed with the lysozyme M
(LysM) Cre line (Tg:LysMCre) in which the Cre recombinase is
expressed in the myeloid lineage [22]. Homozygous conditional Tg:
LysMCre::Cripto/ mice (CriptoMy-LOF) were born in Mendelian
ratio and developed normally. Acute injury was thus induced in
tibialis anterior (TA) muscles of CriptoMy-LOF and Control mice by
CTX injection and injured muscles were analyzed at days 2 and 5
after injury. Deletion of Cripto in the infiltrated MPs was verified by
PCR (Appendix Fig S1A and B). Immunofluorescence analysis of
injured muscle sections stained with F4/80 showed no significant
difference in the F4/80+ area between CriptoMy-LOF and Control
mice at both days 2 and 5 after injury (Fig 2A and B), suggesting
that Cripto genetic ablation did not affect MP accumulation. Given
the expression of Cripto in the anti-inflammatory MPs, we analyzed
this MP population at days 2 and 5 after injury by staining muscle
sections for the anti-inflammatory marker CD206 (Fig 2C). While
the frequency distribution of CD206+ MPs was comparable in
CriptoMy-LOF and Control muscles at day 2 (Fig 2C top panels and
D), a significant decrease in CD206+ MPs was observed in CriptoMy-
LOF at day 5 (Fig 2C bottom panels and E). In order to specifically
identify and characterize Cripto KO MPs, we combined conditional
lineage-tracing and genetic ablation of Cripto. CriptoMy-LOF mice
were thus crossed with the Tg:R26mTmG transgenic line [23] to
obtain the Tg:LysMCre::R26mTmG::Criptofl/fl (GFP-CriptoMy-LOF;
Fig EV2A and B) and the Tg:LysMCre::R26mTmG (GFP-Control) as
control. We first assessed the efficiency of LysMCre-mediated Cripto
deletion by genomic qPCR analysis on Florescence-Activated Cell
Sorting (FACS)-sorted F4/80+ MPs (CriptoMy-LOF) or GFP+ mono-
cytes/MPs (GFP-CriptoMy-LOF). Genomic DNA from heterozygous
Cripto KO (Cripto+/) mice was used as reference for 50% of gene
deletion. The efficiency of Cripto deletion was ~ 50% in the overall
MP population, while it increased up to ~ 80% in the GFP+ popula-
tion (Fig EV2C). Accordingly, ~ 50% of the MP population
expressed the reporter GFP both in GFP-CriptoMy-LOF and GFP-
Control mice (Fig EV2D). Finally, we measured Cripto protein by
ELISA and found that it was significantly reduced in Cripto KO MPs
compared to control (Fig EV2E).
Given that the vast majority (> 90%) of GFP+ cells expressed
F4/80 in both GFP-CriptoMy-LOF and GFP-Control muscles
(Fig 3A), we quantified the percentage of GFP+ cells/MPs at both
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days 2 and 5 after injury and found that it was comparable in
the two groups (Fig 3A), thus providing further evidence that
CriptoMy-LOF did not affect MP accumulation in the injured
muscle. To further investigate the nature of these MPs, CriptoMy-LOF
and Control MPs were FACS-isolated by GFP expression, and the
expression profile of genes associated with either pro- or anti-
inflammatory phenotype analyzed by qRT–PCR at days 2 and 5
after injury. Cripto KO MPs showed a transient increase in the
pro-inflammatory marker Nos2 at day 2, while other pro-inflam-
matory genes (Mcp1, Tnfa) were not affected at both time points
(Fig 3B). Of note, at day 2, Arg1 and Fizz1, which identify the
CD206+ MPs [24], were similarly expressed in the two groups
(Fig 3B), consistent with the equal distribution of the CD206+
MPs at this time point (Fig 2D). Conversely, later on at day 5
both genes were significantly downregulated in Cripto KO cells,
whereas other anti-inflammatory markers (Il10, Il4ra, and Tgfb)
were not affected (Fig 3B). These findings were consistent with
the reduction of the CD206+ MPs in CriptoMy-LOF (Fig 2E) and
provided molecular support for the idea that modulation of MP
phenotypic plasticity is perturbed in the absence of Cripto.
Cripto modulates TGFb signaling in the infiltrating MPs
Fine-tuning of the TGFb signaling plays a key role in shaping MP
identity [13,25] and Cripto is a well-known modulator of TGFb
signaling through interaction with TGF-b family ligands [14]. For
instance, it is known that Cripto attenuates TGFb-1 signaling by
interfering with its binding to the Act-R II receptors [26]. This raised
the possibility that Cripto-dependent modulation of TGFb signaling
might play a role in shaping MP plasticity. We therefore investigated
the status of TGFb signaling in Cripto KO infiltrating MPs by looking
at the phosphorylation of the TGFb effector SMAD3. Immunofluo-
rescence analysis of pSMAD3 and CD206 within the GFP+ cell





Figure 1. Time-course expression of surface Cripto in pro- and anti-inflammatory macrophages in acute skeletal muscle injury.
A Experimental scheme of Cripto expression analysis in macrophage (MP) subpopulations from wild-type skeletal muscles at different time points after cardiotoxin
(CTX) injection.
B Representative flow cytometry dot plots of CD11b+ and CD11b+/Cripto+ cells at days 2, 3, and 5 after injury. PE (Phycoerythrin/free channel). Data are mean  SEM
(n = 5 biological replicates; P ≤ 0.00008, Student’s t-test).
C Representative flow cytometry dot plots of CD11b+/F4/80+/Ly6CHigh/Low and CD11b+/Cripto+/F4/80+/Ly6CHigh/Low cells at days 2, 3, and 5 after injury.
D Quantification of F4/80+/Ly6CHigh/Low cells in the CD11b+ and CD11b+/Cripto+ cell population from injured muscles at the indicated time points. Data represent
mean  SEM (n = 5 biological replicates; ***P < 0.001, Student’s t-test).
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GFP+/CD206 population of CriptoMy-LOF mice, which inversely
correlated with the decrease in GFP/CD206 double-positive cells
(Fig 3C and D). Of note, the expression of both Tgfb and the latent
TGFb binding protein 4 (LTBP4), which binds the latent TGFb
promoting its secretion [13], did not increase in Cripto KO MPs
(Fig 3B and Appendix Fig S2), indicating that neither expression nor
secretion of TGFb was affected and suggesting that loss of Cripto




Figure 2. Myeloid-specific Cripto deletion perturbs MP plasticity without affecting monocyte/macrophage accumulation.
A Representative pictures of immunostaining for F4/80 (green) in Control and CriptoMy-LOF TA sections at days 2 (top panel) and 5 (bottom panel) after injury.
B Quantification of F4/80 staining/damaged area (lm2) at days 2 (top graph) and 5 (bottom graph) after injury.
C Representative pictures of immunostaining for CD206 in Control and CriptoMy-LOF TA sections at days 2 (top panel) and 5 (bottom panel) after injury, respectively.
D, E Quantification of CD206+ MPs per area (mm2) at days 2 (D) and 5 (E) after injury.
Data information: Nuclei were counterstained with DAPI (blue). Scale bar: 50 lm. Magnification of the boxes is 3.5×. Data are expressed as box plots displaying
minimum, first quartile, median, third quartile, and maximum (n ≥ 5 biological replicates; **P < 0.01, Student’s t-test).
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phenotype and based on the observation that Cripto was preferen-
tially expressed in the anti-inflammatory Ly6CLow MPs, concomi-
tantly with their accumulation in the regenerating tissue (Fig 1C),
we compared the molecular signature of wild-type and Cripto KO
Ly6CLow MPs. Of note, FACS analysis of GFP+ cells showed that the
percentage of F4/80+/Ly6CLow MPs was comparable in CriptoMy-LOF
and Control at day 5 after injury (75.9  2.2% in GFP-Control vs.
71.7  3.8 in GFP-CriptoMy-LOF; Fig 3E), indicating that Cripto dele-
tion did not affect the proper downregulation of Ly6C expression.
To further investigate this issue, GFP+/Ly6CLow cells were FACS-
isolated from both groups and total RNA was extracted and
analyzed by RNA-seq. Smear plot analysis of differentially expressed
genes showed no main differences between Control and Cripto KO
dataset (Fig 3F and Dataset EV1), indicating that Cripto KO MPs
carried the overall expression signature of the Ly6CLow MPs and
suggesting that Cripto was dispensable to induce/maintain the
Ly6CLow phenotype.
Altogether, these findings indicated that Cripto acts as an extrin-
sic modulator of MP plasticity and suggested that it is required for
the proper expansion/maintenance of the CD206+ anti-inflamma-
tory MP population.
Cripto-dependent modulation of MP phenotypes promotes
skeletal muscle regeneration in acute injury and disease
We have recently shown that Cripto expression in the infiltrated
MPs cannot compensate for the lack of Cripto in the myogenic
compartment [19], suggesting that Cripto exerts a cell-type-
specific role in the regeneration process. To investigate the effect
of Cripto-dependent modulation of MP phenotypes in the repair
process, we performed morphometric analysis of CriptoMy-LOF and
Control TA muscles at days 5 and 30 after CTX-induced injury
(CTX-I) (Fig 4A and B). Quantification of the minimal Feret’s
diameter of centrally nucleated fibers (CNF) showed no significant
differences in the two groups at both time points (Fig 4C), indi-
cating that regeneration was proceeding normally in CriptoMy-LOF
mice following a single muscle injury. To investigate this pheno-
type further and given the incomplete deletion of Cripto in the
overall MP population (Fig EV2C), we used a more challenging
model of re-injury [27]. To this end, CriptoMy-LOF and Control TA
muscles were injected with CTX and allowed to recover for
30 days; regenerated muscles were then re-injured by a second
CTX injection (CTX-II), and the minimal Feret’s diameter of CNF
was determined at days 5 and 30 after re-injury (Fig 4D and E).
Unlike the absence of phenotype observed after a single muscle
injury (CTX-I), a significant shift toward smaller regenerating
myofibers was detected in CriptoMy-LOF muscles at both days 5
and 30 after re-injury (Fig 4F), which is a clear indication of
altered maturation of regenerating myofibers. Furthermore, the
CD206+ anti-inflammatory MPs significantly decreased in
CriptoMy-LOF TA muscles at day 5 after re-injury (Fig EV3A),
consistent with that observed in the single injury model (Figs 2E
and 3D). Finally, to test whether myeloid Cripto deficiency may
affect the satellite cell compartment, we analyzed the distribution
of Pax7+ satellite cells. A transient reduction in Pax7+ cells was
observed in CriptoMy-LOF at day 5 after single injury, which was
recovered at late time points (Fig EV3B and C).
These findings prompted us to investigate the effect of myeloid
Cripto deficiency in disease conditions, such as in the muscle
dystrophinopathies. To address this issue directly, we extended
the analysis to the mdx mouse, which is a well-characterized
model of Duchenne muscular dystrophy (DMD). Of note, while in
acute injury a precise sequential presence of pro-inflammatory
and anti-inflammatory MPs sustains skeletal muscle repair and
regeneration, in DMD, the two MP populations coexist but fail to
promote tissue repair and homeostasis recovery, eventually lead-
ing to fibrosis and fat deposition [2]. In order to investigate the
effect of myeloid-specific Cripto deletion in adult mdx mice, we
performed transplantation experiments of bone marrow (mutant
or not for myeloid Cripto) into dystrophic mice. Bone marrow
from GFP-CriptoMy-LOF and GFP-Control mice was first trans-
planted into lethally irradiated 4-month-old mdx recipient mice
(107 cells/mouse). Sixteen weeks after transplantation, 8-month-
old CriptoMy-LOF (mdx-CriptoMy-LOF) and Control (mdx-Control)
mice were sacrificed (Fig 5A). FACS analysis showed that a large
majority ( 80%) of the infiltrated MPs were GFP+ in both
mdx-CriptoMy-LOF and mdx-Control muscles (Fig EV4A), indicating
that, as in acute injury, Cripto deletion did not affect MP accumu-
lation in dystrophic muscles. Interestingly, the large majority of
both Control and CriptoMy-LOF GFP+ MPs were Ly6CLow
(Fig EV4B). We thus assessed the distribution of CD206+ MPs in
mdx-CriptoMy-LOF and mdx-Control diaphragms by double staining
for GFP and CD206. GFP-positive cells largely infiltrated the
diaphragm of both mdx-CriptoMy-LOF and mdx-Control mice
◀ Figure 3. Cripto controls the proper expansion of CD206+ MPs by modulating TGFb signaling.A Representative flow cytometry dot plots showing the percentage of GFP+ cell population in GFP-Control and GFP-CriptoMy-LOF muscles at days 2 (top panel) and 5
(bottom panel) after injury. Percentage of GFP+ cells expressing F4/80 in GFP-Control and GFP-CriptoMy-LOF muscles is shown at day 2 after injury (middle panel).
Data are mean  SEM (n = 4 biological replicates; P = ns; Student’s t-test).
B qRT–PCR analysis of pro-inflammatory markers (Nos2, Mcp1, and Tnfa) and anti-inflammatory markers (Arg1, Fizz1, Il10, Il4ra, and Tgfb) in GFP-CriptoMy-LOF and GFP-
Control MPs at days 2 and 5 after injury. Data represent mean  SEM of relative mRNA level normalized with Gapdh (n ≥ 4 biological replicates; ***P < 0.001,
Student’s t-test).
C Representative pictures of immunostaining for GFP (green), CD206 (red), and pSMAD3 (white) in GFP-Control and GFP-CriptoMy-LOF TA sections at day 5 after injury.
Nuclei were counterstained with DAPI (blue). Scale bar: 100 lm. Magnification of the boxes is 3.5×.
D Quantification of GFP+/CD206/pSMAD3 cell distribution in TA sections from GFP-Control and GFP-CriptoMy-LOF at day 5 after injury. Nuclei were counterstained
with DAPI (blue). Scale bar: 100 lm. Data are mean  SEM (n = 5 biological replicates; **P < 0.01, Student’s t-test).
E Representative flow cytometry dot plots of F4/80+/Ly6CLow cell population gated on GFP+ cells from GFP-Control and GFP-CriptoMy-LOF muscles at day 5 after injury.
Data are mean  SEM (n = 3 biological replicates; P = ns; Student’s t-test).
F Smear plot of RNA-seq data from GFP+/F4/80+/Ly6CLow cells FACS sorted from GFP-Control and GFP-CriptoMy-LOF muscles at day 5 after injury. Data show the
expression level as log2 fold change (FC) [log2(GFP-Control/GFP-Cripto
My-LOF)], against log2(expression) [log2(average of gene expression across all samples], for each
individual gene. The blue lines correspond to LogFC of 1 and 1 (n = 3 biological replicates).
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(Fig 5B left panels and C), in line with the idea that this is the
most severely affected muscle in mdx mice [11]. Remarkably,
quantification of the GFP/CD206 double-positive cells revealed a
significant decrease in the CD206+ MPs in mdx-CriptoMy-LOF
compared to Control (Fig 5B left panels and D). Complementary
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and pSMAD3 revealed a positive trend toward increased number
of pSMAD3+ cells in the GFP population (Fig 5B middle and right
panels and E), suggesting a tendency to increased TGFb signaling
also in mdx Cripto KO MPs. Activation of TGFb signaling
promotes mesenchymal transition and fibrosis and contributes to
disease worsening in mdx mice [9,13,28]. Consistent with this
evidence, quantification of collagen deposition/fibrosis by
Picrosirius red staining and hydroxyproline assay showed a signif-
icant increase in collagen accumulation in mdx-CriptoMy-LOF
diaphragm muscles (Fig 5F–H). Complementary to these findings,
minimal Feret’s diameter revealed a significant accumulation in
mdx-CriptoMy-LOF diaphragm muscle of smaller CNF at the
expense of the large fibers (Fig 5I and J). Consistently, increased
variance coefficient of minimal Feret’s diameter indicated a higher
variability of myofiber size in mdx-CriptoMy-LOF mice (Fig 5K).
Furthermore, the density of eMHC-positive myofibers was signifi-
cantly reduced in mdx-CriptoMy-LOF diaphragms (Fig 5L and M),
providing further evidence that myeloid-specific Cripto deletion
reduces the regenerative potential of the mdx diaphragm muscle
leading to exacerbation of the dystrophic phenotype. Consistent
with that observed in acute injury, no significant difference was
found in the number of Pax7+ cells between the two groups
(Fig EV4C), thus suggesting that ablation of myeloid Cripto did
not affect, at least markedly, the satellite cell compartment.
Collectively, these results indicated that myeloid Cripto sustains
accumulation of CD206+ anti-inflammatory MPs in acutely injured
and dystrophic muscles, enhancing muscle regeneration/repair.
CriptoMy-LOF affects endothelial plasticity through modulation of
EndMT in injured and dystrophic muscle
Despite extensive research efforts, knowledge of the specific
contribution of the MP subpopulations to rebuilding the damaged
muscle is still limited. It is known that anti-inflammatory MPs
produce angiogenic factors and promote neovascularization
[29,30]. We therefore investigated the effect of CriptoMy-LOF on
vascular remodeling of injured and dystrophic muscles. Time-
course immunofluorescence analysis for CD31 at days 5 and 30
after single CTX injection (CTX-I) showed a significant reduction
in both capillary density (CD) and area (CA) in CriptoMy-LOF
muscles (Fig 6A–C), whereas no difference was observed in rest-
ing conditions (Appendix Fig S3). Of note, while the reduction in
the CD was transient in CriptoMy-LOF muscles and correlates with
defective accumulation of CD206+ MPs at day 5, reduction in the
CA persisted at day 30, when inflammation is resolved (Fig 6B
and C). To further support the CA analysis at day 5, a separate
quantification of the small and large CA revealed an inverse
distribution of the different capillary sizes in the two groups
(CA < 20 lm2, 31.5  3.7% in Control vs. 41.4  0.6% in
CriptoMy-LOF; CA > 100 lm2, 11.2  1.3% in Control vs.
4.9  0.6% in CriptoMy-LOF; Fig 6D). We then extended the analy-
sis to both re-injured (CTX-II) and dystrophic (mdx) muscles by
staining for CD31 or VE-cadherin (VEcad), respectively (Fig 6E
and F). Consistent with the findings above, CriptoMy-LOF re-injured
and dystrophic muscles showed a significant reduction in CA as
◀ Figure 4. Effect of myeloid-specific Cripto deletion on skeletal muscle regeneration process.A Schematic representation of the experimental design in the single injury model (CTX-I).
B Representative pictures of double immunostaining with laminin (green) and embryonic myosin heavy chain (eMHC; red) at days 5 (left panel) and 30 (right panel)
after cardiotoxin (CTX) injection.
C Minimal Feret’s diameter distribution of Control and CriptoMy-LOF centrally nucleated myofibers at days 5 (top panel) and 30 (bottom panel) after CTX injection. Data
are mean  SEM (n = 5 biological replicates; P = ns, Student’s t-test).
D Schematic representation of the experimental design in the re-injury model (CTX-II).
E Representative pictures of double immunostaining with laminin (green) and eMHC (red) at days 5 (left panel) and 30 (right panel) after re-injury (CTX-II).
F Minimal Feret’s diameter distribution of Control and CriptoMy-LOF centrally nucleated myofibers at days 5 (top panel) and 30 (bottom panel) after re-injury (CTX-II).
Data information: Nuclei were counterstained with DAPI (blue). Scale bar: 100 lm. Data are mean  SEM (n = 5 biological replicates; *P < 0.05, Student’s
t-test).
▸Figure 5. Myeloid-specific Cripto deletion reduced the accumulation of CD206+ MPs and worsens the mdx phenotype.A Schematic representation of the experimental strategy. Four-month-old lethally irradiated mdx mice were transplanted with either GFP-CriptoMy-LOF
(mdx-CriptoMy-LOF) or GFP-Control (mdx-Control) bone marrow and sacrificed at 16 weeks (wks) after transplantation.
B Representative pictures of immunostaining of mdx-Control and mdx-CriptoMy-LOF diaphragm sections with GFP (green) and CD206 (white; left panel), pSMAD3 (red;
middle panel), and GFP and pSMAD3 (right panel).
C–E Quantification of GFP (C)-, GFP/CD206 (D)-, and GFP/pSMAD3 (E)-positive cells per area (mm2) in mdx-Control and mdx-CriptoMy-LOF diaphragms. Data are
expressed as box plots displaying minimum, first quartile, median, third quartile, and maximum (n ≥ 5 biological replicates; **P < 0.01, Student’s t-test).
F, G Representative pictures of Picrosirius red staining of mdx-Control and mdx-CriptoMy-LOF diaphragm sections (F) and quantification of Picrosirius red staining (G).
Data are expressed as percentage of stained area and are box plots displaying minimum, first quartile, median, third quartile, and maximum (n = 5 biological
replicates; *P < 0.05, Student’s t-test).
H Hydroxyproline (HOP) concentration in mdx-Control and mdx-CriptoMy-LOF diaphragm muscle sections. Data are expressed as HOP levels (lg) per muscle section
volume (mm3) and as box plots displaying minimum, first quartile, median, third quartile, and maximum (n = 5 biological replicates; **P < 0.01, Student’s t-test).
I–K Representative images of laminin (red) immunostaining of mdx-Control and mdx-CriptoMy-LOF diaphragm sections (I) and minimal Feret’s diameter distribution (J)
and variance coefficient (VC; K) of centrally nucleated myofibers. Data are expressed as mean  SEM (n = 5 biological replicates; *P < 0.05; ***P < 0.001; Student’s
t-test) and box plots displaying minimum, first quartile, median, third quartile, and maximum (n = 5 biological replicates; **P < 0.01; Student’s t-test).
L, M Representative images of eMHC (red) immunostaining of mdx-Control and mdx-CriptoMy-LOF diaphragm sections (L) and quantification of eMHC+ myofibers per
area (mm2, M). Data are expressed as box plots displaying minimum, first quartile, median, third quartile, and maximum (n = 5 biological replicates; *P < 0.05;
Student’s t-test).
Data information: Nuclei were counterstained with DAPI (blue). Scale bar: 100 lm. Magnification of the boxes is 3.5×.
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well as a trend toward a decreased CD (Fig 6G–J), providing
evidence that Cripto-dependent modulation of CD206+ anti-
inflammatory MPs influenced vascular remodeling.
Emerging evidence points to a key role of infiltrating MPs in
regulating the fate of endothelial-derived progenitor cells. Specifi-
cally, MPs are crucial to restrict the process of Endothelial-to-
Mesenchymal Transition (EndMT) by which endothelial cells (ECs)
loose endothelial markers and functions to acquire a mesenchymal
phenotype [8,9] leading to vascular abnormalities. To date, the
contribution of the different MP populations in the control of
EndMT remains largely unclear. Given the predominant effect of
Cripto KO on the CD206+ MPs, we assumed that CriptoMy-LOF mice
are a suitable model to address this issue. We therefore investigated
the extent of EndMT in CriptoMy-LOF and Control mice. To this end,
TA muscles at day 5 were double stained with the EC markers
(VEcad or CD31) and either the EndMT inducer KLF4 [31] or the
mesenchymal markers TCF4 and PDGFRa (Figs 7A and E, and
EV5A). Quantification analysis revealed a strong, consistent
increase in double-positive VEcad/KLF4 and VEcad/TCF4 (Fig 7B
and C), CD31/TCF4 (Fig 7D), and CD31/PDGFRa (Fig 7F) cells in
CriptoMy-LOF mice compared to Control, indicating increased propen-
sity of ECs to undergo EndMT. The increased tendency to acquire
mesenchymal gene expression was rather specific of the EC popula-
tion since the overall number of CD31/PDGFRa+ cells was compa-
rable between CriptoMy-LOF and Control (Fig 7G).
Several signaling molecules can induce EndMT, which can be
produced either by the resident cells of the injured tissue or by the
infiltrated immune cells. One of the best characterized inducers of
EndMT is TGFb [8,32]. We therefore looked at pSMAD3 in the
VEcad+/KLF4+ cell population by triple immunostaining of muscle
sections for VEcad, KLF4, and pSMAD3 (Figs 7H and EV5B). The
distribution of VEcad/KLF4/pSMAD3 triple-positive cells signifi-
cantly increased in CriptoMy-LOF muscles (Fig 7I), indicating that
increased EndMT positively correlates with increased/persistent
activation of TGFb signaling in ECs. To further investigate the effect
of CriptoMy-LOF on the modulation of vascular remodeling, we
extended the analysis to re-injured and dystrophic muscles (Fig 7J
and K). Consistent with the above findings, the frequency of VEcad/
KLF4 double-positive cells similarly increased in CriptoMy-LOF re-
injured (CTX-II) and dystrophic (mdx-CriptoMy-LOF) muscles (Fig 7L
and M). Of note, we could not observe any significant increase in
EndMT in CriptoMy-LOF muscles at days 2 and 3 after single injury
(Fig EV5C and D). Similarly, no difference was found in the
CD206+ MP population between CriptoMy-LOF and Control at these
time points (Fig 2C and D, and Appendix Fig S4). Thus, our
evidence of an invariable inverse correlation between the abun-
dance of CD206+ MPs and the extent of EndMT pointed to a key
role of this MP population in restricting EndMT.
Altogether, these findings provided evidence that Cripto-depen-
dent modulation of the MP phenotype controls vascular remodeling
in injured and dystrophic muscles, at least in part, by counteracting
TGFb-induced EndMT.
Discussion
Macrophage (MP) polarization is a highly dynamic process and it
is now clear that the M1/M2 phenotypes only define the extremes
of a phenotypic continuum, with MPs often displaying characteris-
tics of both states at the same time in vivo [33]. The molecular
basis of this plasticity is still far to be elucidated also due to the
fact that in vitro polarization poorly mimics the complexity of
in vivo conditions, including for instance the influence of microen-
vironment. In the present study, we reveal a key role of the extra-
cellular membrane protein Cripto in shaping MP phenotypes in
injured and dystrophic muscles. Specifically, we used the intramus-
cular injection of cardiotoxin (CTX) as a model of acute muscle
injury. Although the CTX injection is not physiological and the
muscle damage is different to that induced by exercise or chronic
disease, it is a widely used model since it induces a sequential and
synchronous skeletal muscle regeneration characterized by neutro-
phil and macrophage infiltration [27]. We provide unprecedented
evidence that Cripto is predominantly expressed at the membrane
of anti-inflammatory (Ly6CLow) MPs, which progressively infiltrates
the muscle following CTX-induced acute injury. In line with its
expression profile, myeloid-specific Cripto genetic ablation
(CriptoMy-LOF) reduces the number of CD206+ anti-inflammatory
MPs both in acute injury and in disease.
Molecular and immunofluorescence analysis indicate that while
the CD206+ MPs are present in normal number in CriptoMy-LOF
muscles at early time point after acute injury, they are significantly
reduced later on, concomitantly to the time of their increase in the
regenerating muscle. It thus stands to reason that this anti-inflam-
matory MP population is induced but then fail to properly expand/
accumulate in the absence of Cripto. Since myeloid-specific Cripto
KO does not affect macrophage accumulation, it is reasonable to
assume that CriptoMy-LOF MPs show a mixed phenotype. In line with
this idea, while the expression of key anti-inflammatory genes (Arg1
and Fizz1) is reduced in Cripto KO MPs at day 5 after injury, consis-
tent with the reduced CD206+ MPs, other anti-inflammatory-specific
◀ Figure 6. Myeloid-specific Cripto deletion affects vascular remodeling.A Representative pictures of CD31 (red) immunostaining of Control and CriptoMy-LOF TA sections at days 5 (left panel) and 30 (right panel) after single injury (CTX-I).
B–D Quantification of CD31+ capillary number per area (mm2; B), average of capillary cross-sectional area (lm2; C), and percentage of small (< 20 lm2) and large
(> 100 lm2) capillaries (D) in Control and CriptoMy-LOF injured muscles at indicated time points after single injury (CTX-I). Data are mean  SEM (n = 5 biological
replicates; *P < 0.05; **P < 0.01; ***P < 0.001, Student’s t-test).
E Representative pictures of CD31 (red) immunostaining of Control and CriptoMy-LOF TA sections at days 5 (left panel) and 30 (right panel) after re-injury (CTX-II).
F Representative pictures of mdx-Control and mdx-CriptoMy-LOF diaphragm sections immunostained with VEcad (red).
G, H Quantification of CD31+ capillary number per area (mm2; G) and average of capillary cross-sectional area (lm2; H) in Control and CriptoMy-LOF injured muscles at
the indicated time points after re-injury (CTX-II). Data are mean  SEM (n = 6 biological replicates; *P < 0.05; ***P < 0.001, Student’s t-test).
I, J Quantification of capillary number per area (mm2; I) and average of capillary cross-sectional area (lm2; J) in mdx-Control and mdx-CriptoMy-LOF diaphragm
muscles. Data are mean  SEM (n = 5 biological replicates; ***P < 0.001, Student’s t-test).
Data information: Nuclei were counterstained with DAPI (blue). Scale bar: 100 lm. Magnification of the boxes is 3.5×.
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genes, including Il10, Il4ra, and Tgfb, are not affected, pointing to
perturbation of MP plasticity rather than impaired phenotypic
transition.
Recent findings suggest that at early stage of acute injury, infil-
trating MP populations are broadly activated rather than polarized,
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findings are in line with this assumption; for instance, the anti-
inflammatory genes Arg1 and Fizz1 are already expressed at day 2
after injury. It is thus tempting to speculate that Cripto expression at
the early time point may also reflect the broad activation of the infil-
trated MPs. Interestingly, at this early stage of acute injury, Cripto
genetic ablation affects neither pro- nor anti-inflammatory gene
expression, with the exception of the pro-inflammatory marker
Nos2. Conversely, several lines of evidence indicate that Cripto
controls the proper distribution of CD206+ MPs in acute injury and
disease. First, the number of CD206+ MPs is consistently reduced in
CriptoMy-LOF injured and dystrophic muscles. Furthermore, CriptoMy-
LOF affects neither the frequency of the GFP+/F4/80+/Ly6CLow anti-
inflammatory MPs nor their genome-wide expression profile,
providing support to the idea that Cripto is dispensable for the
induction and maintenance of the Ly6CLow MP population, but it is
rather required for the maintenance and/or expansion of the
CD206+ MP phenotype.
MPs change their phenotypes in response to different stimuli in
the microenvironment, among which TGFb plays a crucial role.
Indeed, MPs secrete high level of latent TGFb protein, which
becomes activated [13], and mediate the crosstalk with other muscle
cellular components including ECs, fibroblasts, and fibro-adipogenic
precursors (FAPs) [9]. TGFb signaling is modulated via the control
of a large repertoire of extracellular and membrane proteins, which
regulate the strength of the signaling and the cell-specific response,
including Cripto [35]. Indeed, Cripto can attenuate TGFb-1 signaling
by interfering with its binding to the Act-R II receptors [26] thus
raising the possibility that Cripto-dependent control of MP plasticity
may occur, at least in part, through modulation of TGFb/Smad
signaling. In line with this hypothesis, we find a strong increase in
pSMAD3+ cells in the CD206 MP population in Cripto KO mice,
which inversely correlates with the reduction in the CD206+ MPs.
The inverse correlation between the number of pSMAD3+ and
CD206+ MPs suggests that a persistent/aberrant activation of
TGFb/Smad signaling prevents, at least in part, the proper expan-
sion of the CD206+ anti-inflammatory MPs in the absence of Cripto.
This Cripto-dependent modulation of MP plasticity contributes to
efficient regeneration/maturation of muscle fibers both in acute
injury and in chronic disease conditions. We thus propose that,
while myeloid Cripto is dispensable for macrophage polarization, it
contributes, along with other factors, to create the proper inflamma-
tory microenvironment for muscle repair and regeneration.
In line with the idea that Cripto exerts a cell-type-specific role in
muscle repair [19], myeloid Cripto ablation does not significantly
affect the satellite cell number, suggesting the involvement of other
cell types. It is known that anti-inflammatory MPs exert a key role
in the rebuilding of skeletal muscle by producing anti-inflammatory
cytokines and by secreting pro-angiogenic factors that promote
vascular remodeling. Furthermore, MPs play a crucial role in shap-
ing the fate of endothelial-derived progenitor cells by restricting the
process known as Endothelial-to-Mesenchymal Transition (EndMT)
by which ECs loose endothelial markers and functions and acquire a
mesenchymal phenotype [8–10]. Several lines of evidence suggest
that this phenotypic switch likely occurs as a continuum with
temporal changes in the expression of endothelial and mesenchymal
markers [36]. How this multistep process is controlled, and whether
intermediate/plastic phenotypes can be maintained without
progressing toward a fully mesenchymal state is a major unresolved
issue. So far, the contribution of MPs to the process of EndMT in
skeletal muscle, and their functional interaction with other muscle
cell population, has been investigated by using chemical/toxin-
induced depletion of MPs [4,8,10,37]. Thus, the specific contribu-
tion of the different and occasionally antagonistic MP phenotypes to
this process remains poorly understood. Here, we provide evidence
that the CD206+ MPs exert a key role in regulating EndMT both in
injured and dystrophic muscles. Specifically, we show that the
reduction in the CD206+ MPs invariably correlates with increased
EndMT in CriptoMy-LOF mice, pointing to a key role of Cripto in this
complex scenario. It is reasonable to assume that Cripto may exert
its activity either directly, as a paracrine factor produced by the anti-
inflammatory MPs, or indirectly through regulating maintenance/
expansion of CD206+ MP population. The invariable inverse corre-
lation between the CD206+ MPs and the extent of EndMT would
favor the hypothesis that a proper expansion/maintenance of these
anti-inflammatory MPs is a crucial condition to prevent excessive
EndMT.
Increased TGFb signaling is major contributor to excessive
EndMT and fibrosis, and predictor of chronic muscle disease wors-
ening [12]. Yet, the specific contribution of the pro- and anti-inflam-
matory MPs to this scenario is still a question of debate and data are
somehow controversial. Here, we show that reduced accumulation
of CD206+ MPs associates with increased EndMT and fibrosis in
mdx-CriptoMy-LOF mice. Although we cannot assume any causative
correlation between increased EndMT and fibrosis, we suggest that
◀ Figure 7. Cripto modulates endothelial plasticity by restricting Endothelial-to-Mesenchymal Transition.A Representative pictures of double immunostaining with VEcad (red; left and middle panels) and KLF4 (green, left panel) or TCF4 (green, middle panel), and with
CD31 (red; right panels, confocal pictures) and TCF4 (white, right panel) on Control and CriptoMy-LOF TA sections at day 5 after injury.
B–D Quantification of VEcad/KLF4 (B), VEcad/TCF4 (C), and CD31/TCF4 (D) double-positive cells per area (mm2) in Control and CriptoMy-LOF TA sections at day 5 after
injury.
E Representative Confocal pictures of CD31+ (red) and PDGFRa+ (green) immunostaining on Control and CriptoMy-LOF TA sections at day 5 after injury.
F, G Quantification of CD31+/PDGFRa+ (F) and CD31/PDGFRa+ (G) cells per area (mm2).
H, I Representative pictures of triple immunostaining with VEcad (red), KLF4 (green), and pSMAD3 (white) on Control and CriptoMy-LOF TA sections at day 5 after injury
(H) and quantification of VEcad/KLF4/pSMAD3 triple-positive cells per area (mm2; I).
J, K Representative pictures of double immunostaining with VEcad (red) and KLF4 (green) on Control and CriptoMy-LOF TA sections at day 5 after re-injury (CTX-II; J) and
on diaphragm sections of mdx-Control and mdx-CriptoMy-LOF (K).
L, M Quantification of VEcad/KLF4 double-positive cells per area (mm2) in Control and CriptoMy-LOF TA sections at day 5 after re-injury (CTX-II; L) and in diaphragm
sections of mdx-Control and mdx-CriptoMy-LOF (M).
Data information: Nuclei were counterstained with DAPI (blue). Scale bar: 100 lm. Confocal pictures scale bar: 25 lm. Magnification of the boxes is 3.5×. Data are
expressed as box plots displaying minimum, first quartile, median, third quartile, and maximum (n ≥ 5 biological replicates; *P < 0.05; **P < 0.01; ***P < 0.001;
Student’s t-test).
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accumulation/expansion of CD206+ MPs contributes to myofiber
regeneration/maturation in dystrophic mice, preventing excessive
collagen deposition. In line with this idea, it has been recently
showed that anti-inflammatory MPs are associated to areas with
regenerating myofibers in mdx mice [13].
Collectively, these findings point to a previously unknown role
for Cripto as a regulator of MP plasticity and EndMT in skeletal
muscle acute injury and disease. The human relevance of our find-
ings remains to be determined. Indeed, human and mouse immune
system exhibit extensive similarities; however, some differences
have been reported [38]. For instance, how the continuum of
human and murine macrophages phenotypes is aligned is still
unclear [39]. Thus, although differences may exist between mouse
and human MP phenotypes, CriptoMy-LOF mice provide a unique
genetic model to study the specific contribution of CD206+ anti-
inflammatory MP population in different pathologies where
inflammation play a critical role, including vascular disease and
cancer.
Materials and Methods
Mouse models and genotyping
Experiments were done in accordance with the law on animal exper-
imentation (article 7; D.L. 116/92) under the Animal Protocol
approved by the Department of Public Health, Animal Health, Nutri-
tion and Food Safety of the Italian Ministry of Health. Bone marrow
transplantation experiments were approved by the ethics committee
of the Barcelona Biomedical Research Park (PRBB) and by the Cata-
lan Government.
Experimental mice were 10–12 weeks old, if not differently speci-
fied. We did not perform randomization for blinded experiments in
this animal study. The Tg:LysMCre::Criptofl/fl mice (CriptoMy-LOF)
were generated by crossing the Tg:LysMCre strain (Jackson stock
number 004781) [22] to Tg:Criptofl/fl transgenic mice [21]. Tg:
LysMCre::R26mTmG::Criptofl/fl (GFP-CriptoMy-LOF) mice were obtained
by crossing the Tg:LysMCre::Criptofl/fl mice to the Tg:R26mTmG
reporter line [23]. Mice genotyping was performed by PCR using
primers listed in Appendix Table S1. To quantify the efficiency of
Cripto deletion, quantitative real-time PCR (qPCR) of wild-type
Cripto allele was performed on genomic DNA samples. The amount
of wild-type Cripto was measured by using specific primers that
amplify a DNA region encompassing exon 4, inside the LoxP-
flanked region. Sequence-specific primers were designed to amplify
exon 2, outside the LoxP-flanked region, that was used as reference
PCR. The amount of wild-type Cripto was calculated over the refer-
ence PCR. Primers are listed in Appendix Table S1.
Nucleic acid extraction and quantitative RT–PCR analysis
Genomic DNA was isolated by a standard phenol–chloroform
method using an SDS/NaCl extraction buffer (200 mM Tris–HCl pH
7.5, 25 mM EDTA, 250 mM NaCl, and 0.5% SDS).
Total RNAs were isolated in TRIzol (Sigma-Aldrich) by using the
Direct-Zol Miniprep Kit (Zymo Research) following manufacturer’s
instructions, and reverse transcribed using QuantiTect Reverse
Transcription Kit (Qiagen). Quantitative real-time PCR (qPCR) was
performed using SYBR GREEN PCR Master Mix (FluoCycle IITM
SYBR, EuroClone). Primers are listed in Appendix Table S2.
Muscle injury, histological, and immunofluorescence analysis
To induce muscle damage, 20, 30 ll, or 50 ll of cardiotoxin (CTX;
Latoxan, 10 lM) was injected in the tibialis anterior (TA), gastroc-
nemius, and quadriceps muscle, respectively. Muscles were
collected and embedded in OCT (Bio-Optica) or directly snap-frozen
in liquid nitrogen-cooled isopentane for cryosection, as previously
described [40].
Immunofluorescence (IF) staining was performed on serial
muscle sections (10 lm). After fixation in PFA 4% (wt/vol), muscle
sections were permeabilized with 0.2% Triton X-100 (Sigma), 1%
BSA in PBS for 30 min at room temperature and then blocked in
10% serum, 1% BSA in PBS for 60 min, before incubation with the
primary antibody for overnight at 4°C. Appropriate fluorochrome-
conjugated antibodies were used as second-step reagent. For Pax7
visualization, muscle sections were processed as previously
described [41]. Briefly, cryosections were fixed in 4% (wt/vol) PFA
and permeabilized in ice-cold methanol for 6 min at 20°C. Slides
were subjected to antigen retrieval in boiling 10 mM Na-citrate (pH
6.0) solution for 15 min, followed by cooling for 30 min. Sections
were then incubated in blocking buffer with 4% IgG-free BSA (Jack-
son) in PBS for 2 h, and endogenous immunoglobulins were
blocked with AffiniPure Fab Fragment Goat Anti-Mouse IgG (Jack-
son) for 30 min at room temperature. Primary antibody was incu-
bated overnight at 4°C. Biotin-conjugated secondary antibody and
Alexa Fluor 488-conjugate streptavidin (Invitrogen; S32354) were
used for the detection. Nuclei were counterstained with DAPI (1 lg/
ml; Roche), and FluorSave Reagent (Calbiochem) was used for
mounting. Primary and secondary antibodies used are listed in
Appendix Table S3.
Images acquisition and analyses
Bright-field and fluorescent images were taken by using DM6000B
(Leica), ECLIPSE NI-E (Nikon), or Confocal TCS SP5 (Leica) micro-
scopes. Immunofluorescence images showing double and triple flu-
orescence were acquired separately by using appropriate filters.
The different layers were then merged and edited by using Adobe
Photoshop CS6. Histological quantifications were performed
considering all regenerating areas (20× magnification or 40×
magnification).
For quantifying the F4/80-positive area, images were processed
through the threshold tool of the ImageJ software to segment out
and measure the staining areas. For quantification of CD31- or
VEcad-positive staining, the signal from CD31 or VEcad immunos-
taining was processed by using the ImageJ software as previously
described [42]. An empirically determined threshold was used to
segment out CD31- or VEcad-positive regions, thereby calculating
the density and area of capillaries by using the Analyze Particles
tool of the ImageJ software.
Morphometric analyses were performed on sections collected
from similar regions of each muscle. Minimal Feret’s diameter of
muscle fibers was determined on immunostained sections (500–
1,000 fibers/muscle) using the ImageJ software. Variance coefficient
of minimal Feret’s diameter was calculated as reported [43].
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For collagen quantification, 10-lm-thick sections were stained
with Sirius Red (Sigma-Aldrich) according to standard procedures.
Briefly, sections were incubated with 0.1% Sirius Red solution
dissolved in aqueous saturated picric acid for 1 h, washed rapidly in
2% acetic acid, dehydrated, and mounted with DPX Mounting.
Collagen content was calculated as a percentage of the red-stained
area/section using ImageJ (https://imagej.nih.gov/ij/docs/example
s/stained-sections/).
Florescence-activated cell sorting
Muscles were removed and separated from the bones, and dissoci-
ated by enzymatic digestion using 3 U/ml Dispase II (Roche),
0.5 U/ml Collagenase A (Roche), 10 lg/ml DNAse I (Roche),
400 lM CaCl2, and 5 lM MgCl2 in phosphate-buffered saline (PBS),
for 75 min in a shaking bath at 37°C. Cells were then washed with
DMEM (Gibco) and filtered with 100- and 70-lm cell strainers
(Corning). Following filtration, red blood cells were removed using
BD Pharm LyseTM (BD Biosciences) according to the manufacturer’s
instructions, and the remaining cells were re-suspended in PBS 2%
FBS (FACS buffer). Macrophages were blocked using purified Rat
Anti-Mouse CD16/CD32 (Mouse BD Fc BlockTM; 1:100) for 15 min at
4°C and then incubated with the indicated primary antibodies for
30 min at 4°C. After washing with ice-cold PBS, cells were either
analyzed or sorted with a FACSAria II (BD Biosciences); data were
analyzed with FACSDiva software (BD Biosciences). Free channel
was used to exclude auto-fluorescent cells from the analysis.
Primary antibodies used are listed in Appendix Table S3.
ELISA
To quantify Cripto protein, 96-well plate was coated with mouse
anti-Cripto antibody (100 ll, 0.5 lg/ml) in PBS (pH 7.5) overnight
at 4°C and washed three times with PBS-Tween. Unbinding sites
were blocked with 1% PBS-BSA (180 ll/well) for 3 h at room
temperature (RT). After three washing, protein extracts obtained
from 1 × 106 FACS-sorted GFP+ cells were diluted in PBS, 0.1%
BSA, 5 mM EDTA, 0.004% Tween-20 (PBET) with a final volume of
100 ll and incubated overnight at 4°C. Recombinant mouse Cripto
(R&D Systems) was used to obtain a standard curve concentration.
After washing, the plate was incubated with anti-Cripto biotinylated
antibody (1 lg/ml; R&D Systems) in PBET for 1 h at 37°C and then
for 1 h at RT. Finally, the plate was incubated for 1 h at RT with
avidin/streptavidin complex conjugated with HRP (VECTASTAIN
Elite ABC Kit; Vector Laboratories), and developed with o-phenyle-
nediamine peroxidase substrate (Sigma-Aldrich). Absorbance was
read at 490 nm on a Benchmark Microplate Reader (Bio-Rad Labo-
ratories).
Hydroxyproline assay
To determine hydroxyproline (HOP) content in diaphragm muscles,
two 10-lm-thick muscle sections/mouse were processed and
analyzed using the Hydroxyproline Colorimetric Assay (Sigma-
Aldrich; MAK008-1KT), according to the manufacturer’s instruc-
tions. Absorbance was read at 560 nm on a Synergy HT Microplate
Reader (BioTek). HOP levels were normalized by the volume of
muscle sections to yield lg/mm3.
Whole-genome expression analysis
Sequencing read quality was assessed with FastQC [44]. Available
online at http://www.bioinformatics.babraham.ac.uk/projects/fa
stqc).
Over-represented sequences were trimmed with Cutadapt 1.7.1
(http://journal.embnet.org/index.php/embnetjournal/article/view/
200), which also discarded reads that were shorter than 30 bp. The
resulting reads were mapped against the mouse transcriptome
(GRCm38, release 91; dec2017 archive) and quantified using RSEM
v1.2.20 [45]. Data were then processed with a differential expres-
sion analysis pipeline that used Bioconductor package LIMMA [46]
for normalization and differential expression testing. Finally, to
visualize the differential expression of each individual gene, log2
average of gene expression level and log2 fold change between
Control and KO condition have been reported, respectively, on the
x-axis and y-axis of smear plot.
Bone marrow transplantation
For bone marrow transplantation, 10-wk-old GFP-CriptoMy-LOF or
GFP-Control mice were used as donors. Bone marrow of donor mice
was flushed from femur and tibia bones, and ~ 1 × 107 cells were
transplanted into lethally irradiated C57BL/10ScSn-Dmdmdx/J (mdx)
4-mo-old recipient mice. No-transplanted animals were used as
control of irradiation, which generally die 7–21 days after the irradi-
ation.
Statistical analysis
The exact sample size for each experiment is reported as “n” in the
caption of each figure. Animals or samples were not randomized
during experiments and not excluded from analyses. The investiga-
tors were not blinded to group allocation during experiments and
outcome analyses. Statistical analyses were performed using
unpaired two-sided Student’s t-tests, and P < 0.05 was considered
statistically significant. Results are presented as the mean  SEM
(standard error of the mean) or as box plot displaying minimum,
first quartile, median, third quartile, and maximum. Box plots were
generated using RStudio software (https://www.rstudio.com/).
Data availability
The dataset produced in this study is available in the following data-
base: Gene Expression Omnibus GSE142072 (https://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE142072).
Expanded View for this article is available online.
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